木瓜直播

Participants in a phase I trial lost a placebo-adjusted 6.1% of their body weight after 4 weeks of treatment with the investigational oral , Roche announced.

JAMA on medications for obesity.

BMI is still "a valuable method" for defining obesity despite its flaws, argued authors of an opinion piece.

Abbott plans to use TV ads and guerilla marketing in the U.S. launch of its for people without diabetes. (Reuters)

Cumulative exposure to insulin-like growth factor 1 excess may be in acromegaly but not in clinically nonfunctioning pituitary adenoma, a longitudinal study suggested. (Journal of Clinical Endocrinology & Metabolism)

Yet another health implication : a higher risk for type 2 diabetes. (Diabetes Care)

Patients are concerned about ongoing , as insulin companies may consider GLP-1 receptor agonists to be the new moneymakers. (STAT)

The therapeutic potential of modulating gut microbiota for the purpose of mitigating obesity and metabolic diseases deserves further research, according to researchers in the .

Novo Nordisk said it's "disappointed" that the Dutch government decided (Wegovy) for weight loss management under the country's basic insurance. (Reuters)

Comment